Pierre Legault - Dec 20, 2021 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Director
Signature
/s/ Michael A. Metzger, as Attorney-in-Fact
Stock symbol
SNDX
Transactions as of
Dec 20, 2021
Transactions value $
-$617,736
Form type
4
Date filed
12/22/2021, 05:25 PM
Next filing
Jan 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $142K +20K +125% $7.08 36K Dec 20, 2021 Direct
transaction SNDX Common Stock Sale -$420K -20K -55.56% $21.01 16K Dec 20, 2021 Direct F1, F2
transaction SNDX Common Stock Options Exercise $189K +24K +150% $7.88 40K Dec 22, 2021 Direct
transaction SNDX Common Stock Sale -$528K -24K -60% $22.01 16K Dec 22, 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -20K -100% $0.00* 0 Dec 20, 2021 Common Stock 20K $7.08 Direct F4
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -24K -100% $0.00* 0 Dec 22, 2021 Common Stock 24K $7.88 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 63,000 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested.
F2 The sale prices ranged from $21.00 to $21.0238.
F3 The sale prices ranged from $22.00 to $22.02.
F4 This option is fully vested.